Similarly, F2, derived from the FAK inhibitor IN10018, has shown inhibitory activity against several cancer cell lines, reversing multidrug resistance (MDR) by targeting AKT and ERK signaling pathways while reducing P-glycoprotein (P-gp) levels, with IC50 values ranging from 0.73 to 5.84 μM [84]. Here, AKT1 is linked to cancer.